# OnCo record g1-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/g1-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "g1-therapeutics" ;
  schema:name "G1 Therapeutics"@en ;
  schema:alternateName "G1 Therapeutics, Inc."@en, "G1"@en ;
  schema:description "G1 Therapeutics developed trilaciclib (Cosela), a CDK4/6 inhibitor given before chemotherapy to protect bone marrow, approved in 2021 for small-cell lung cancer; the company was acquired by Pharmacosmos in 2024."@en ;
  schema:url <https://onco.cc/companies/g1-therapeutics/> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?lead=G1%20Therapeutics>, <https://en.wikipedia.org/wiki/G1_Therapeutics> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/sclc/>, <https://onco.cc/cancers/tnbc/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/> ;
  onco:drugs <https://onco.cc/drugs/lerociclib/> ;
  onco:terms <https://onco.cc/terms/neutropenia/> .